n-caproylsphingosine has been researched along with Prostatic-Hyperplasia* in 1 studies
1 other study(ies) available for n-caproylsphingosine and Prostatic-Hyperplasia
Article | Year |
---|---|
Traditional Chinese Medicine Danzhi qing'e decoction inhibits inflammation-associated prostatic hyperplasia via inactivation of ERK1/2 signal pathway.
Inflammation plays a critical role during benign prostatic hyperplasia (BPH) development. Danzhi qing'e (DZQE) decoction is a traditional Chinese medicine that has been widely used for estrogen and androgen-related diseases. However, its effect on inflammation-related BPH remains unclear.. To investigate the effect of DZQE on inhibition of inflammation-related BPH, and further identify the possible mechanism involved.. Experimental autoimmune prostatitis (EAP)-induced BPH was established and then 2.7 g/kg of DZQE was administrated orally for 4 weeks. The prostate sizes, weights and prostate index (PI) values were recorded. Hematoxylin and eosin (H&E) was performed for pathological analyses. Macrophage infiltrate was evaluated by Immunohistochemical (IHC). The inflammatory cytokine levels were measured by Rt-PCR and ELISA methods. The phosphorylation of ERK1/2 was examined by Western blot. The expression differences of mRNA expressions between EAP-induced and oestrogen/testosterone (E2/T)-induced BPH was investigated by RNA sequencing analyses. In vitro, human prostatic epithelial BPH-1 cells were stimulated with the conditioned medium from monocyte THP-1-derived M2 macrophages (M2CM), followed by treatment of Tanshinone IIA (Tan IIA), Bakuchiol (Ba), ERK1/2 antagonist PD98059 or ERK1/2 agonist C6-Ceramide. The ERK1/2 phosphorylation and cell proliferation were then detected by Western blotting and CCK8 assay.. DZQE suppressed inflammation-associated BPH via regulation of ERK1/2 signal by Tan IIA and Ba. Topics: Animals; Cytokines; Estrogens; Humans; Inflammation; Male; MAP Kinase Signaling System; Medicine, Chinese Traditional; Prostatic Hyperplasia; Rats; Signal Transduction | 2023 |